• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

Research Briefing on Dichloro(1,3-dimesityl-2-imidazolidinylidene)[2-(2-oxopropoxy)benzylidene]ruthenium (CAS: 1014701-61-1)

Recent advancements in the field of chemical biology and medicinal chemistry have highlighted the significance of ruthenium-based complexes, particularly Dichloro(1,3-dimesityl-2-imidazolidinylidene)[2-(2-oxopropoxy)benzylidene]ruthenium (CAS: 1014701-61-1). This complex, belonging to the family of N-heterocyclic carbene (NHC) ruthenium catalysts, has garnered attention due to its unique catalytic properties and potential therapeutic applications. The following briefing synthesizes the latest research findings on this compound, focusing on its synthesis, mechanistic insights, and emerging applications in drug discovery and development.

The synthesis of Dichloro(1,3-dimesityl-2-imidazolidinylidene)[2-(2-oxopropoxy)benzylidene]ruthenium involves a multi-step process that leverages the robust coordination chemistry of ruthenium with NHC ligands. Recent studies have optimized the synthetic protocol to improve yield and purity, with particular emphasis on the role of the oxopropoxybenzylidene moiety in stabilizing the complex. Advanced spectroscopic techniques, including NMR and X-ray crystallography, have been employed to confirm the structural integrity of the compound, revealing a distorted octahedral geometry around the ruthenium center.

Mechanistic studies have elucidated the compound's catalytic activity in various organic transformations, such as olefin metathesis and hydrogenation reactions. The presence of the NHC ligand enhances the electron density at the ruthenium center, thereby increasing its reactivity and selectivity. Notably, the compound has demonstrated exceptional stability under physiological conditions, making it a promising candidate for biomedical applications. Recent in vitro studies have explored its potential as an anticancer agent, with preliminary results indicating selective cytotoxicity against certain cancer cell lines.

In the context of drug discovery, Dichloro(1,3-dimesityl-2-imidazolidinylidene)[2-(2-oxopropoxy)benzylidene]ruthenium has been investigated for its ability to modulate key biological pathways. For instance, it has shown inhibitory effects on protein kinases involved in cell proliferation and survival. Additionally, its role as a photosensitizer in photodynamic therapy (PDT) has been explored, with promising results in preclinical models. These findings underscore the compound's versatility and potential as a multifunctional therapeutic agent.

Despite these advancements, challenges remain in translating the compound's preclinical success into clinical applications. Issues such as bioavailability, toxicity, and targeted delivery need to be addressed through further research. Recent efforts have focused on developing nanoparticle-based delivery systems to enhance the compound's pharmacokinetic profile. Collaborative studies between chemists and biologists are essential to overcome these hurdles and unlock the full therapeutic potential of this ruthenium complex.

In conclusion, Dichloro(1,3-dimesityl-2-imidazolidinylidene)[2-(2-oxopropoxy)benzylidene]ruthenium represents a cutting-edge example of how transition metal complexes can bridge the gap between chemical catalysis and medicinal chemistry. Its unique structural and functional attributes make it a valuable tool for both synthetic chemists and biomedical researchers. Future studies should aim to expand its applications, optimize its therapeutic efficacy, and explore its mechanisms of action in greater detail. This briefing serves as a foundation for ongoing and future research endeavors in this exciting area of chemical biology.

• 301224-40-8([1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichloro-[(2-isopropoxyphenyl)methylene]ruthenium)
• 1438000-18-0(nitro-Grela)
• 927429-61-6(Dichloro[1,3-Bis(2-Methylphenyl)-2-Imidazolidinylidene](2-Isopropoxyphenylmethylene)Ruthenium(II))
• 1030618-11-1(Dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]{[5-(2-ethoxy-2-oxoethanamido)]-2-isopropoxybenzylidene}ruthenium(II))
• 502964-52-5((SP-5-41)-1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidenedichloro2-(1-methylethoxy-kO)-5-nitrophenylMethylene-kC-ruthenium)
• 635679-24-2([1,3-Bis[2,6-di(propan-2-yl)phenyl]imidazolidin-2-ylidene]-dichloro-[(2-propan-2-yloxyphenyl)methylidene]ruthenium)
• 1031262-71-1(1,3-BIS(2,4,6-TRIMETHYLPHENYL)-2-IMIDAZOLIDINYLIDENE]DICHLORO[[2-(1-METHYLACETOXY)PHENYL]METHYLENERUTHENIUM(II))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)